Международная разработка
ClinicalTrials.gov
Исследования, вмешательства, заболевания, спонсоры, страны и результаты.
Фокус анализа
салметерол, флутиказон
580
записей в выборке
Варианты написания учтены салметерол → salmeterol · флутиказон → fluticasone Подробнее Скрыть
- салметерол → salmeterol проверенная транслитерация · 100% Основание: версионированный словарь · словарь 1.1.0 Поиск: salmeterol, салметерол, сальметерол, салметерола ксинафоат, salmeterol xinafoate, sal meterol
- флутиказон → fluticasone проверенная транслитерация · 100% Основание: версионированный словарь · словарь 1.1.0 Поиск: fluticasone, флутиказон, flutikazon, флютиказон, флутиказона пропионат, fluticasone propionate
Для поиска доступны 597 478 исследований AACT · ClinicalTrials.gov. Показано совпадений: 66.
Результаты
ClinicalTrials.gov
факт источника
аналитический сигнал
Фильтры реестра По столбцам текущей таблицы Не заданы
| Исследование | Вмешательство / заболевание | Спонсор / страны | Фаза и статус | Сроки / участники | Результаты |
|---|---|---|---|---|---|
| Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate NCT00102882 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Kenya, Peru, Puerto Rico, United States | PHASE4 Завершено | 31.10.2004 — 31.01.2007 547 участников | Не найдены Первоисточник ↗ |
| A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations ↗ NCT00116402 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Pulmonary Disease, Chronic Obstructive
|
University of Chicago United States | PHASE1 Завершено | 31.01.2005 — 31.10.2009 15 участников | Не найдены Первоисточник ↗ |
| A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise ↗ NCT00118690 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Bronchospasm, Activity/Exercise Induced Bronchospasm
|
GlaxoSmithKline United States | PHASE4 Завершено | 31.12.2003 — 31.12.2005 227 участников | Не найдены Первоисточник ↗ |
| A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise ↗ NCT00118716 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Bronchospasm, Activity/Exercise Induced Bronchospasm
|
GlaxoSmithKline United States | PHASE4 Завершено | 23.12.2003 — 23.04.2006 248 участников | Опубликованы Первоисточник ↗ |
| Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies. NCT00169546 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline New Zealand, United Kingdom | PHASE4 Завершено | 31.01.2003 — 31.12.2005 64 участников | Не найдены Первоисточник ↗ |
| Study In Asthma Control NCT00273026 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Canada | PHASE4 Прекращено | 08.11.2004 — 28.03.2006 680 участников | Не найдены Первоисточник ↗ |
| Study Of Patients With Allergic Rhinitis And Asthma NCT00296530 AACT · ClinicalTrials.gov |
fluticasone
montelukast
salmeterol
Asthma
|
GlaxoSmithKline United States | PHASE4 Завершено | 30.09.2005 — 31.07.2007 600 участников | Не найдены Первоисточник ↗ |
| Viapaed Study In Children And Adolescents With Asthma NCT00315744 AACT · ClinicalTrials.gov |
fluticasone
salbutamol
salmeterol
Asthma
|
GlaxoSmithKline Germany | PHASE4 Завершено | 04.11.2004 — 12.04.2007 285 участников | Не найдены Первоисточник ↗ |
| Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids NCT00353873 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Belgium, Denmark, France, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Russia, Spain, Sweden | PHASE4 Завершено | 18.11.2005 — 26.10.2006 506 участников | Опубликованы Первоисточник ↗ |
| Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics NCT00364442 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Germany | PHASE1 Завершено | 28.01.2005 — 13.04.2005 12 участников | Не найдены Первоисточник ↗ |
| Spacer Comparison In Adult Asthmatics NCT00369993 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline New Zealand | PHASE2 Завершено | 31.03.2005 — 31.05.2005 20 участников | Не найдены Первоисточник ↗ |
| Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies. NCT00370591 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline United Kingdom | PHASE4 Завершено | 31.12.2002 — 30.04.2004 48 участников | Не найдены Первоисточник ↗ |
| Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) NCT00395304 AACT · ClinicalTrials.gov |
fluticasone
montelukast
salmeterol
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.03.2007 — 31.12.2011 182 участников | Опубликованы Первоисточник ↗ |
| A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease ↗ NCT00403286 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
formoterol fumarate
Chronic Obstructive Pulmonary Disease
|
Dey United States | PHASE2 Завершено | 30.11.2006 — 31.05.2007 457 участников | Не найдены Первоисточник ↗ |
| A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma NCT00441441 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Australia, Canada, Chile, Costa Rica, Germany, Latvia, Lithuania, Mexico, Peru, Poland, Russia, Spain, United States | PHASE3 Завершено | 28.02.2007 — 31.01.2008 351 участников | Опубликованы Первоисточник ↗ |
| Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma NCT00448435 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
gw815sf hfa mdi
Bronchial Asthma
|
GlaxoSmithKline Japan | PHASE3 Завершено | 30.04.2007 — 31.01.2008 51 участников | Опубликованы Первоисточник ↗ |
| Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS) NCT00480649 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline South Korea | PHASE4 Завершено | 31.01.2004 — 30.09.2005 424 участников | Не найдены Первоисточник ↗ |
| Study Of RV-39 In Patients Who Also Have Asthma NCT00503009 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline United States | PHASE4 Прекращено | 31.10.2007 — 31.07.2008 16 участников | Опубликованы Первоисточник ↗ |
| Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD ↗ NCT00530842 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
tiotropium plus salmeterol
Pulmonary Disease, Chronic Obstructive
|
Boehringer Ingelheim Austria, Canada, France, Germany, Italy, Russia, Sweden | PHASE4 Завершено | 30.09.2007 — — 344 участников | Опубликованы Первоисточник ↗ |
| Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma ↗ NCT00557440 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
indacaterol maleate
mometasone
mometasone furoate
+2
Asthma
|
Novartis Belgium, Germany | PHASE2 Завершено | 30.11.2007 — 30.04.2008 37 участников | Опубликованы Первоисточник ↗ |
| Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange ↗ NCT00568347 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone 100mcg
fluticasone 250
salmeterol 50
salmeterol 50mcg
+3
COPD
|
Arthur F Gelb MD United States | Фаза не указана Завершено | 31.01.2006 — 31.10.2013 39 участников | Не найдены Первоисточник ↗ |
| Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma ↗ NCT00576069 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
mometasone
prednisone
+3
Asthma
|
Gelb, Arthur F., M.D. United States | Фаза не указана Набор участников | 25.10.2007 — 30.06.2027 60 участников | Не найдены Первоисточник ↗ |
| Symbicort Onset of Action 2 ↗ NCT00646009 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
albuterol
budesonide
formoterol
+2
Asthma
|
AstraZeneca Страны не указаны | PHASE3 Завершено | 31.03.2003 — 31.08.2003 48 участников | Не найдены Первоисточник ↗ |
| Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT00662805 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.06.2004 — 30.09.2008 762 участников | Не найдены Первоисточник ↗ |
| Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma ↗ NCT00736801 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Allergic Asthma
|
University of Rostock Germany | Фаза не указана Завершено | 30.09.2005 — 30.04.2007 35 участников | Не найдены Первоисточник ↗ |
| A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). ↗ NCT00784550 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
tiotropium bromide
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline United States | PHASE4 Завершено | 31.12.2008 — 31.12.2009 342 участников | Опубликованы Первоисточник ↗ |
| Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma ↗ NCT00830505 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 30.04.2009 — 31.05.2010 38 участников | Не найдены Первоисточник ↗ |
| Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers ↗ NCT00908362 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Smoke-related Lung Diseases, Chronic Obstructive Pulmonary Disease
|
University of Rostock Germany | PHASE1 Завершено | 31.05.2009 — 31.12.2009 45 участников | Не найдены Первоисточник ↗ |
| Sub-Sensitivity to Long-Acting Bronchodilators (LABA) ↗ NCT01117116 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
+1
Asthma
|
National Jewish Health United States | Фаза не указана Завершено | 31.03.2010 — 30.09.2013 20 участников | Опубликованы Первоисточник ↗ |
| Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01186653 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
+1
Chronic Obstructive Pulmonary Disease
|
Hull University Teaching Hospitals NHS Trust United Kingdom | PHASE4 Завершено | 31.10.2007 — 31.05.2010 22 участников | Не найдены Первоисточник ↗ |
| A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma ↗ NCT01202097 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
seretide
Asthma
|
Eurofarma Laboratorios S.A. Brazil | PHASE3 Завершено | 31.08.2011 — 31.05.2012 334 участников | Не найдены Первоисточник ↗ |
| Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD ↗ NCT01209715 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
COPD
|
University of Miami United States | PHASE2 Отозвано | 31.10.2010 — 31.05.2012 0 участников | Не найдены Первоисточник ↗ |
| Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway ↗ NCT01231230 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
University of Miami Страны не указаны | Фаза не указана Завершено | 31.05.2007 — 31.08.2010 14 участников | Опубликованы Первоисточник ↗ |
| The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD ↗ NCT01243788 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Chronic Obstructive Pulmonary Disease (COPD)
|
Fudan University China | PHASE4 Статус не определён | 31.07.2009 — 31.10.2011 450 участников | Не найдены Первоисточник ↗ |
| QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01315249 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
glycopyrronium qva149
indacaterol
+1
Chronic Obstructive Pulmonary Disease (COPD)
|
Novartis Pharmaceuticals Belgium, Czechia, Estonia, Germany, Hungary, Lithuania, Norway, South Korea, Spain | PHASE3 Завершено | 31.03.2011 — 31.03.2012 523 участников | Опубликованы Первоисточник ↗ |
| Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone) ↗ NCT01332409 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Japan | Фаза не указана Завершено | 31.08.2009 — 31.01.2013 2 000 участников | Не найдены Первоисточник ↗ |
| Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric) ↗ NCT01332422 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.11.2009 — 30.11.2012 300 участников | Не найдены Первоисточник ↗ |
| Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population ↗ NCT01337336 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
anticholinergics
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 31.10.2010 — 31.03.2011 1 участников | Опубликованы Первоисточник ↗ |
| Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) ↗ NCT01395849 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Respiratory Disorders
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 31.10.2007 — 31.03.2011 2 116 участников | Не найдены Первоисточник ↗ |
| Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) ↗ NCT01395862 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Respiratory Disorders
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.11.2007 — 30.09.2012 1 001 участников | Не найдены Первоисточник ↗ |
| Phase I Pharmacokinetic Study (SALBLOCK) ↗ NCT01564199 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Healthy Volunteer Study
|
Orion Corporation, Orion Pharma Finland | PHASE1 Завершено | 30.04.2012 — 30.06.2012 20 участников | Не найдены Первоисточник ↗ |
| A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 ↗ NCT01709903 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qva149
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Argentina, Chile, China, Taiwan | PHASE3 Завершено | 30.11.2012 — 28.02.2014 744 участников | Опубликованы Первоисточник ↗ |
| Dose-ranging Study ↗ NCT01712451 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Abdominal Contour Defects
|
Neothetics, Inc United States | PHASE2 Завершено | 31.08.2011 — 31.10.2012 200 участников | Не найдены Первоисточник ↗ |
| A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects ↗ NCT01751113 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
salmeterol plus tiotropium bromide
tiotropium bromide
+1
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Japan | PHASE4 Завершено | 28.02.2013 — 30.11.2013 53 участников | Опубликованы Первоисточник ↗ |
| WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects ↗ NCT01763463 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 31.07.2012 — 31.05.2013 1 участников | Не найдены Первоисточник ↗ |
| A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01817764 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
umeclidinium
vilanterol
+1
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Argentina, Chile, Greece, Peru, Romania, Ukraine, United States | PHASE3 Завершено | 01.03.2013 — 25.10.2013 707 участников | Опубликованы Первоисточник ↗ |
| A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01822899 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
diskus
umeclidinium bromide
vilanterol
+2
Pulmonary Disease, Chronic Obstructive
|
GlaxoSmithKline Czechia, Denmark, Germany, Hungary, Netherlands, Poland, Russia, Spain | PHASE3 Завершено | 04.04.2013 — 07.10.2013 717 участников | Опубликованы Первоисточник ↗ |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD ↗ NCT01834885 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qva149
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Austria, Germany | PHASE3 Отозвано | 31.12.2013 — 30.09.2014 0 участников | Не найдены Первоисточник ↗ |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD ↗ NCT01860066 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qva149
Chronic Obstructive Pulmonary Disease
|
Novartis Pharmaceuticals Argentina, Belgium, Colombia, Czechia, India | PHASE3 Отозвано | 31.12.2013 — 30.09.2014 0 участников | Не найдены Первоисточник ↗ |
| Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) ↗ NCT01908140 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
aclidinium bromide
formoterol fumarate
+1
Chronic Obstructive Pulmonary Disease (COPD)
|
AstraZeneca Austria, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom | PHASE3 Завершено | 30.09.2013 — 31.08.2014 933 участников | Опубликованы Первоисточник ↗ |
| A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid ↗ NCT02094274 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
las40468
Asthma
|
Almirall, S.A. Germany, United Kingdom | PHASE1 Завершено | 30.11.2013 — 31.05.2014 30 участников | Не найдены Первоисточник ↗ |
| Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older ↗ NCT02437604 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE1 Завершено | 31.05.2015 — 30.09.2015 43 участников | Не найдены Первоисточник ↗ |
| Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol ↗ NCT02491970 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
formoterol
Asthma
|
Mundipharma Korea Ltd Страны не указаны | PHASE4 Прекращено | 31.08.2015 — 31.05.2017 15 участников | Не найдены Первоисточник ↗ |
| A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma ↗ NCT02554786 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
indacaterol acetate
mometasone furoate
+1
Asthma
|
Novartis Pharmaceuticals Bulgaria, China, Croatia, Czechia, Egypt, Estonia, Germany, Guatemala, Hungary, India, Ireland, Japan, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, United Kingdom, United States | PHASE3 Завершено | 29.12.2015 — 28.06.2019 2 216 участников | Опубликованы Первоисточник ↗ |
| Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma ↗ NCT02571777 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
160
320
50
80
qmf149 150
qvm149 150
+5
Asthma
|
Novartis Pharmaceuticals Argentina, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, Vietnam | PHASE3 Завершено | 08.12.2015 — 14.06.2019 3 092 участников | Опубликованы Первоисточник ↗ |
| Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma ↗ NCT02573233 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
dupilumab sar231893
formoterol
mometasone furoate
regn668
+4
Asthma
|
Sanofi Canada, Denmark, Germany, Sweden, United Kingdom, United States | PHASE2 Завершено | 27.01.2016 — 03.01.2018 42 участников | Опубликованы Первоисточник ↗ |
| Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD ↗ NCT02603393 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qva149
tiotropium
+1
Chronic Obstructive Pulmonary Disease (COPD)
|
Novartis Pharmaceuticals Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Germany, Greece, Hungary, Latvia, Lithuania, Netherlands, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom | PHASE4 Завершено | 20.11.2015 — 18.07.2017 1 053 участников | Опубликованы Первоисточник ↗ |
| Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate ↗ NCT02649478 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
50
advair diskus 100
+1
Asthma
|
Roxane Laboratories United States | Фаза не указана Завершено | 31.08.2014 — 30.11.2015 1 430 участников | Не найдены Первоисточник ↗ |
| A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma ↗ NCT02680561 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone propionate mdpi
salmeterol mdpi
+1
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE1 Завершено | 30.04.2016 — 31.08.2016 20 участников | Не найдены Первоисточник ↗ |
| Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler ↗ NCT02980133 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Georgia, Hungary, Russia, Ukraine, United States | PHASE3 Завершено | 28.12.2016 — 13.04.2019 841 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma ↗ NCT03207243 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
gsk3772847
Asthma
|
GlaxoSmithKline Australia, Canada, Mexico, Russia, Ukraine, United States | PHASE2 Завершено | 14.09.2017 — 15.05.2019 165 участников | Опубликованы Первоисточник ↗ |
| Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years ↗ NCT03387241 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
formoterol
Asthma
|
Mundipharma (China) Pharmaceutical Co. Ltd China | PHASE3 Статус не определён | 02.06.2017 — 30.03.2020 330 участников | Не найдены Первоисточник ↗ |
| Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. ↗ NCT03468790 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
cmab007
symbicort
ventolin
+2
Asthma, Allergic
|
Shanghai Biomabs Pharmaceutical Co., Ltd. China | PHASE3 Завершено | 09.05.2018 — 09.03.2021 393 участников | Не найдены Первоисточник ↗ |
| Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg) ↗ NCT03535870 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
100 mcg 50 mcg inhalation powder
advair diskus
+1
Asthma
|
West-Ward Pharmaceutical United States | Фаза не указана Завершено | 26.04.2018 — 10.09.2019 1 556 участников | Не найдены Первоисточник ↗ |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. ↗ NCT05776927 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qvm149
Asthma
|
Novartis Pharmaceuticals Страны не указаны | PHASE3 Набор ещё не начат | 31.07.2026 — 30.01.2029 188 участников | Не найдены Первоисточник ↗ |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma ↗ NCT06676319 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
albuterol
budesonide
formoterol
lunsekimig
short acting beta agonists saba
+4
Asthma
|
Sanofi Argentina, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Poland, Romania, South Africa, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States | PHASE2 Активно, набор завершён | 07.11.2024 — 19.07.2027 556 участников | Не найдены Первоисточник ↗ |